TY  - JOUR
T1  - COnsumer group asks fda to warn patients about hypertension combination therapy
AU  - Mitka M
Y1  - 2012/11/28
N1  - 10.1001/jama.2012.25362
JO  - JAMA
SP  - 2070
EP  - 2071
VL  - 308
IS  - 20
N2  - 
At issue are medications containing angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and the direct renin inhibitor aliskiren. Individually, these medications do lower blood pressure, and it was theorized that combining the therapies could confer a synergistic benefit in patients with hypertension and other conditions, such as chronic kidney disease. Indeed, such benefits are seen in many patients given combination therapy often involving a thiazide-type diuretic and another hypertension treatment medication. Combining ACE inhibitors and ARBs has been shown to be effective in reducing proteinuria and reducing cardiovascular death or hospital admissions in patients with chronic heart failure. But otherwise, studies appearing over the past decade not only have shown no benefit to this approach, but also have identified increased risk for adverse events, prompting Public Citizen's petition. 

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.25362
UR  - http://dx.doi.org/10.1001/jama.2012.25362
ER  -